RRBP1 is highly expressed in prostate cancer and correlates with prognosis
Authors Li T, Wang Q, Hong X, Li H, Yang K, Li J, Lei B
Received 6 September 2018
Accepted for publication 8 February 2019
Published 23 April 2019 Volume 2019:11 Pages 3021—3027
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Rituraj Purohit
Tieqiu Li,1 Qianqian Wang,2 Xiuqin Hong,3 Huahua Li,4 Ke Yang,1 Jiahui Li,1 Bin Lei5
1Department of Urology, Hunan Provincial People’s Hospital, First Affiliated Hospital of Hunan Normal University, Changsha 410005, People’s Republic of China; 2Department of Oncology, The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan 412007, People’s Republic of China; 3Institute of Gerontology, Hunan Provincial People’s Hospital, First Affiliated Hospital of Hunan Normal University, Changsha 410005, People’s Republic of China; 4Department of Geriatric, Hunan Provincial People’s Hospital, First Affiliated Hospital of Hunan Normal University, Changsha 410005, People’s Republic of China; 5Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, People’s Republic of China
Objective: Recently, ribosome binding protein 1 (RRBP1) is reported to be involved in tumorigenesis. However, the expression and clinical significance of RRBP1 in prostate cancer (PCa) remains unknown. This study is aimed to investigate the expression and clinical significance of RRBP1 in PCa.
Materials and methods: RRBP1 expression was firstly detected in 6 cases of PCa and matched adjacent non-cancerous prostate tissues by reverse transcription-quantitative PCR (RT-qPCR) and Western blot. Then, RRBP1 expression was further detected in 127 cases of PCa and 40 cases of non-cancerous prostate tissues by immunohistochemistry (IHC). The relationship of RRBP1 with clinical-pathological characters and patients’ prognosis was analyzed in PCa.
Results: RT-qPCR and Western blot analysis showed that RRBP1 expression levels in PCa tissues were significantly higher compared with those in matched adjacent non-cancerous prostate tissues. IHC results shown that the high-expression rate of RRBP1 in PCa was 69.3%, which was significantly greater than those in non-cancerous prostate tissues (15.0%, P<0.001). RRBP1 expression was significantly associated with T stage, lymph node metastasis, PSA and Gleason score in PCa. Survival analysis indicated that patients with RRBP1 low-expression presented longer survival time compared with those with RRBP1 high-expression. Moreover, RRBP1 as well as T stage, lymph node metastasis and Gleason score could serve as independent prognostic factors in PCa.
Conclusion: RRBP1 is highly expressed in PCa and correlates with prognosis, which may serve as a potential biomarker in PCa.
Keywords: prostate cancer, RRBP1, prognosis, PSA, Gleason score
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]